cholecalciferol and Helicobacter-Infections

The successful eradication rates with standard clarithromycin-based triple therapy are declining concerning the high antibiotic resistance rate and adverse drug reactions. This study aims to evaluate the effect of adding 1,25-hydroxyvitamin D3 on the eradication rates of the standard clarithromycin-based triple therapy for Helicobacter pylori infection.. This is a randomized prospective comparative study of 150 patients diagnosed with H. pylori gastritis using magnifying narrow-band imaging endoscopy and supported by a stool antigen test. Patients were divided into two groups: group A (n = 75) treated with amoxicillin, clarithromycin, and esomeprazole for 2 weeks; group B (n = 75) treated with 1,25-hydroxyvitamin D3 for 1 month plus amoxicillin, clarithromycin, and esomeprazole for 2 weeks. The H. pylori eradication rates were assessed using stool antigen test conducted 4 weeks after the end of therapy. Furthermore, the H. pylori eradication rates were assessed with per-protocol (PP) and intention-to-treat (ITT) analyses.. The current results showed that H. pylori eradication was achieved in 46 of 62 (74.19%) and 46 of 75 (61.33%) patients via PP and ITT analyses, respectively, in group A. However, eradication was achieved in 60 of 68 (88.23%) and 60 of 75 (80%) patients via PP and ITT analyses, respectively, in group B. Therefore, the H. pylori eradication rates in the group where vitamin D3 was added to the clarithromycin-based triple therapy were significantly higher than in the other groups (p = 0.012 and p = 0.029 in ITT and PP analyses, respectively).. Adding vitamin D3 to the standard clarithromycin-based triple therapy could provide an additional advantage to achieve significantly higher eradication rates for H. pylori infection.

Topics: Anti-Bacterial Agents; Cholecalciferol; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies

Owing to the emergence and spread of multidrug resistance mechanisms in. We established an. Our results demonstrated that. This study indicates the advantage of combining vitamin D3 and probiotic to attenuate

Topics: Anti-Inflammatory Agents; Cholecalciferol; Epithelial Cells; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Inflammation; Levilactobacillus brevis

A previous study by our group demonstrated that a vitamin D

Topics: Anti-Bacterial Agents; Cholecalciferol; Helicobacter Infections; Helicobacter pylori; Humans; Microbial Sensitivity Tests; Phosphatidylethanolamines

Topics: Acetylglucosaminidase; Acid Phosphatase; Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Autophagosomes; Autophagy; Autophagy-Related Protein 5; Calcium; Carrier Proteins; Cathelicidins; Cell Line; Cholecalciferol; Epithelial Cells; Helicobacter Infections; Helicobacter pylori; Humans; Lysosomes; Male; Mice, Inbred C57BL; Protein Disulfide-Isomerases; Receptors, Calcitriol; STAT3 Transcription Factor; Stomach; Transient Receptor Potential Channels

Rosacea is a common, chronic, cutaneous disorder presenting with recurrent episodes of facial flushing, erythema, papules, pustules and telangiectasias. It is a multifactorial disease and its various clinical presentations probably represent the consequence of combined different triggers upon a specific background. Its management is largely based on long-established treatments empirically tailored to the specific presenting symptoms and no real breakthrough has occurred to date. However, recent insights into the still rather obscure pathophysiology of rosacea seem to open the way for etiologically oriented treatments. These may include, on the one side, the more effective application of traditional drugs, such as tetracyclines and metronidazole, to specifically selected patients or, on the other side, new therapeutic options, such as vitamin D receptor antagonists. It is to be remarked that the quality of most studies evaluating rosacea treatment is rather poor, mainly due to a lack of proper standardization. For a major breakthrough to occur in the management of rosacea, we need both a better understanding of its pathogenesis and the adherence of future clinical trials to clearly defined grading and inclusion criteria, which are crucial for investigators to correctly compare and interpret the results of their work.

Topics: Adrenergic alpha-Agonists; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antimicrobial Cationic Peptides; Bacillus; Blind Loop Syndrome; Cathelicidins; Cholecalciferol; Gastrointestinal Tract; Helicobacter Infections; Helicobacter pylori; Humans; Mite Infestations; Permethrin; Phototherapy; Rosacea; Skin